About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, The ...

Moderna (MRNA) came out with a quarterly loss of $3.33 per share versus the Zacks Consensus Estimate of a loss of $3.47. This compares to loss of $3.62 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 4.03%. A quarter ago, it was expected that this biotechnology company would post a loss of $3.59 per share when it actually produced a loss of $3.07, delivering a surprise of 14.48%. Over the last four quarters, the company has s ...

Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period. While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights. The consensus estimate for 'Revenue- Product sales' stands at $102.49 million. The estimate indicates ...

Moderna (MRNA) will report second-quarter earnings on Aug 1, before the opening bell. The Zacks Consensus Estimate for sales and earnings is pegged at $124.9 million and a loss of $3.47 per share, respectively. Both metrics indicate significant declines from the year-ago quarter's levels. MRNA's loss estimates have remained consistent at $7.46 per share for 2024 and $5.29 for 2025 in the past 30 days. | --- | --- | --- | --- | --- | |----------------------------------------------|-------|-------|-------|--- ...

MRNA Stock Outperforms Industry, Sector & S&P 500 Encouraging Upcoming Launches Moderna (MRNA) has risen 22.1% in the year-to-date period against the industry's 2.7% fall, as seen in the chart below. The stock also outperformed the sector and the S&P 500. Shares of the company are currently trading above its 200-day moving average. Image Source: Zacks Investment Research Despite registering a significant fall in top-line due to lower COVID-19 vaccine sales, Moderna's shares continue to soar this year on the ...

Discounted stock prices make these strong brands worth considering as investments. Let's take a look at two stocks that trade down significantly from recent highs and see why they might be good stocks to buy right now. Smart investors see that disparity and know it means there are some discounted stocks to be found. The trick, of course, is discerning which of the discounted stocks represent quality companies experiencing a short-term issue (or issues). Not every stock that falls is a wise investment. Howev ...

Group 1: Healthcare Sector Outlook - The outlook for many healthcare stocks is positive, partly due to large investors avoiding the sector, believing it will yield poor returns as long as interest rates remain high [1] Group 2: Walgreens Boots Alliance (WBA) - Walgreens is facing tough competition from large retail chains like Walmart and Target, and increased use of direct mail prescription services has negatively impacted its earnings, which fell to 63 cents per share from 99 cents year-over-year [3] - Analysts predict Walgreens' earnings per share will decline to $2.79 in 2025 from $3.98 in 2023 [4] - The company has significant challenges, including high settlements related to the opioid crisis, resulting in a debt of $33.66 billion and only $711 million in cash as of the end of Q1 [10] - Increased shoplifting and inflation have further hurt Walgreens' financial results, making consumers less willing to pay high prices compared to competitors [19] Group 3: Cassava Sciences (SAVA) - Cassava's only major drug candidate, simufilam, is under scrutiny after Professor Hoau-Yan Wang was indicted for allegedly falsifying data, which could jeopardize the drug's Phase 3 trials [5][11] - If the FDA finds that Cassava knowingly submitted false data, it could lead to severe consequences for the company and a significant drop in its stock price [6][11] - Cassava has been accused of manipulating clinical trial results, raising concerns about the drug's efficacy [12][22] Group 4: Moderna (MRNA) - Moderna's revenue from its Covid-19 vaccine dropped significantly by two-thirds to $6.7 billion last year, as public concern about the virus decreased [14] - Analysts expect Moderna's revenue to decline to $3.85 billion this year from $6.85 billion in 2023 [15] - Moderna's RSV vaccine efficacy is reported at 50% after 18 months, which is less impressive compared to GSK's vaccine that was approved earlier [24]

Core Insights - Moderna announced a $176 million federal grant to develop a bird flu vaccine for humans, focusing on the H5 influenza virus which poses a significant risk to both birds and humans [1][2] - The grant is part of the Rapid Response Partnership Vehicle (RRPV) from the U.S. Department of Health and Human Services, aimed at accelerating mRNA-based vaccine development [2] - Moderna has initiated a Phase 1/2 trial for the H5 influenza vaccine in 2023, with results expected this year to inform further development plans [3][6] Financial Impact - Following the announcement of the federal grant, Moderna's shares increased by 0.5% to $116.54, marking a 17% rise in share value so far in 2024 [4][7] Public Health Context - The CDC reported four human cases of bird flu since 2022, with the WHO documenting 254 cases globally since January 2023, highlighting the ongoing public health concern [5]

Moderna has secured $176 million in federal funding to develop mRNA vaccines against a potential bird flu pandemic, the Boston-based company announced Tuesday, a move that could bolster U.S. vaccine stockpiles as health officials and experts worry the highly contagious H5N1 influenza virus tearing through poultry farms and cattle herds could spread to humans . Getty Images Moderna said the U.S. government funds will bankroll "late-stage development for an mRNA-based vaccine" against H5 influenza virus to en ...

The CHMP's recommendation will now be reviewed by the European Commission (EC) and a final decision is expected shortly. If authorized, mResvia will be Moderna's second approved product in the region. The above news comes just a few days after Moderna suffered a major setback after the U.S. Centers for Disease Control and Prevention (CDC) revised their recommendation for the use of RSV vaccines for the upcoming respiratory virus season. This recommendation is based on data from data from the phase III Conqu ...